Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

basimglurant

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Mood disorders represent the largest cause of disability worldwide. The monoaminergic deficiency hypothesis, which has dominated… Expand
Is this relevant?
2017
2017
Abstract 1. The emerging technique of employing intravenous microdose administration of an isotope tracer concomitantly with an… Expand
Is this relevant?
2017
2017
Basimglurant, a novel mGlu5-negative allosteric modulator under development for the treatment of major depressive disorder, is… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2017
2017
Alzheimer's disease amyloid-β (Aβ) oligomers are synaptotoxic, inappropriately increasing extracellular glutamate concentration… Expand
Is this relevant?
Highly Cited
2016
Highly Cited
2016
IMPORTANCE Antagonism of the postsynaptic metabotropic glutamate subtype 5 receptor is a novel approach to modulate glutamatergic… Expand
Is this relevant?
Review
2016
Review
2016
Chronic stress-related psychiatric conditions such as anxiety, depression, and alcohol abuse are an enormous public health… Expand
  • figure 4
  • table 1
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Major depressive disorder (MDD) is a serious public health burden and a leading cause of disability. Its pharmacotherapy is… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2015
2015
Negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5) have potential for the treatment of… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
Introduction: Metabotropic glutamate receptor 5 (mGlu5) negative allosteric modulators (NAM) such as 2-Methyl-6-(phenylethynyl… Expand
Is this relevant?
2015
2015
Major depressive disorder (MDD) is a serious public health burden and a leading cause of disability. Its pharmacotherapy is… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?